Healthcare systems worldwide are dealing with increasing number of patients with impaired immune response due to several factors: HIV has become chronic disease due to advances in diagnostics and treatment, many patients take immunosuppressive medications to control inflammatory or autoimmune conditions. Also, chemotherapy for oncological diseases involves weakening of the immune system. These patients are often at increased risk of infections, some of which may be preventable by vaccination. However, immune response and protection acquired by vaccination may be impaired on these patients.
At SGVI, we are interested in studying the immune response to vaccinations in groups of immunocompromised patients, especially in People Living with HIV (PLWH). We have several on-going studies focusing on vaccine immunogenicity in immunocompromised patients at SGVI:
This is a phase IV, open label, interventional clinical trial sponsored by SGUL and funded by GSK to study safety and immunogenicity of two meningitis vaccines: MenACWY (Menveo®) and 4CMenB (Bexsero®) in adult patients with HIV infection.
- Propositive Follow-up:
The second phase study after Propositive, sponsored by SGUL and funded by GSK, investigating long-term immunogenicity of MenACWY (Menveo®) and 4CMenB (Bexsero®) in the cohort of adult patients with HIV infection recruited to the Propositive study.
- COVID-19 vaccines and HIV (David to fill in)